Economic Burden of Cancer in the US: Estimates, Projections, and Future Research
Identifieur interne : 002A28 ( Pmc/Curation ); précédent : 002A27; suivant : 002A29Economic Burden of Cancer in the US: Estimates, Projections, and Future Research
Auteurs : K. Robin Yabroff [États-Unis] ; Jennifer Lund [États-Unis] ; Deanna Kepka [États-Unis] ; Angela Mariotto [États-Unis]Source :
- Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [ 1055-9965 ] ; 2011.
Abstract
The economic burden of cancer in the US is substantial and expected to increase significantly in the future due to expected growth and aging of the population and improvements in survival as well as trends in treatment patterns and costs of care following cancer diagnosis. In this paper, we describe measures of the economic burden of cancer and present current estimates and projections of the national burden of cancer in the US. We discuss ongoing efforts to characterize the economic burden of cancer in the US and identify key areas for future work, including developing and enhancing research resources, improving estimates and projections of economic burden, evaluating targeted therapies, and assessing the financial burden for patients and their families. This work will inform efforts by health care policy makers, healthcare systems, and employers to improve the cancer survivorship experience in the US.
Url:
DOI: 10.1158/1055-9965.EPI-11-0650
PubMed: 21980008
PubMed Central: 3191884
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A29
Links to Exploration step
PMC:3191884Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Economic Burden of Cancer in the US: Estimates, Projections, and Future Research</title><author><name sortKey="Yabroff, K Robin" sort="Yabroff, K Robin" uniqKey="Yabroff K" first="K. Robin" last="Yabroff">K. Robin Yabroff</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Lund, Jennifer" sort="Lund, Jennifer" uniqKey="Lund J" first="Jennifer" last="Lund">Jennifer Lund</name><affiliation wicri:level="2"><nlm:aff id="A2">Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, North Carolina</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Kepka, Deanna" sort="Kepka, Deanna" uniqKey="Kepka D" first="Deanna" last="Kepka">Deanna Kepka</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Mariotto, Angela" sort="Mariotto, Angela" uniqKey="Mariotto A" first="Angela" last="Mariotto">Angela Mariotto</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21980008</idno><idno type="pmc">3191884</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191884</idno><idno type="RBID">PMC:3191884</idno><idno type="doi">10.1158/1055-9965.EPI-11-0650</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">002A29</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002A29</idno><idno type="wicri:Area/Pmc/Curation">002A28</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002A28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Economic Burden of Cancer in the US: Estimates, Projections, and Future Research</title><author><name sortKey="Yabroff, K Robin" sort="Yabroff, K Robin" uniqKey="Yabroff K" first="K. Robin" last="Yabroff">K. Robin Yabroff</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Lund, Jennifer" sort="Lund, Jennifer" uniqKey="Lund J" first="Jennifer" last="Lund">Jennifer Lund</name><affiliation wicri:level="2"><nlm:aff id="A2">Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, North Carolina</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Caroline du Nord</region></placeName><wicri:cityArea>Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill</wicri:cityArea></affiliation></author><author><name sortKey="Kepka, Deanna" sort="Kepka, Deanna" uniqKey="Kepka D" first="Deanna" last="Kepka">Deanna Kepka</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author><author><name sortKey="Mariotto, Angela" sort="Mariotto, Angela" uniqKey="Mariotto A" first="Angela" last="Mariotto">Angela Mariotto</name><affiliation wicri:level="2"><nlm:aff id="A1">Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</nlm:aff><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda</wicri:cityArea></affiliation></author></analytic><series><title level="j">Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</title><idno type="ISSN">1055-9965</idno><idno type="eISSN">1538-7755</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">The economic burden of cancer in the US is substantial and expected to increase significantly in the future due to expected growth and aging of the population and improvements in survival as well as trends in treatment patterns and costs of care following cancer diagnosis. In this paper, we describe measures of the economic burden of cancer and present current estimates and projections of the national burden of cancer in the US. We discuss ongoing efforts to characterize the economic burden of cancer in the US and identify key areas for future work, including developing and enhancing research resources, improving estimates and projections of economic burden, evaluating targeted therapies, and assessing the financial burden for patients and their families. This work will inform efforts by health care policy makers, healthcare systems, and employers to improve the cancer survivorship experience in the US.</p></div></front></TEI><pmc article-type="research-article" xml:lang="en"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9200608</journal-id><journal-id journal-id-type="pubmed-jr-id">2299</journal-id><journal-id journal-id-type="nlm-ta">Cancer Epidemiol Biomarkers Prev</journal-id><journal-title-group><journal-title>Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</journal-title></journal-title-group><issn pub-type="ppub">1055-9965</issn><issn pub-type="epub">1538-7755</issn></journal-meta><article-meta><article-id pub-id-type="pmid">21980008</article-id><article-id pub-id-type="pmc">3191884</article-id><article-id pub-id-type="doi">10.1158/1055-9965.EPI-11-0650</article-id><article-id pub-id-type="manuscript">NIHMS319751</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Economic Burden of Cancer in the US: Estimates, Projections, and Future Research</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yabroff</surname><given-names>K. Robin</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lund</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kepka</surname><given-names>Deanna</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mariotto</surname><given-names>Angela</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD</aff><aff id="A2"><label>2</label>Department of Epidemiology, University of North Carolina, Gillings School of Global Public Health, Chapel Hill, North Carolina</aff><author-notes><corresp id="cor1">Please address correspondence and requests for reprints to: K. Robin Yabroff, PhD, MBA, Health Services and Economics Branch/Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Executive Plaza North, Room 4005, 6130 Executive Blvd., MSC 7344, Bethesda, MD 20892-7344, phone (301) 594-1723, <email>yabroffr@mail.nih.gov</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>23</day><month>8</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>10</month><year>2011</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>10</month><year>2012</year></pub-date><volume>20</volume><issue>10</issue><fpage>2006</fpage><lpage>2014</lpage><abstract><p id="P1">The economic burden of cancer in the US is substantial and expected to increase significantly in the future due to expected growth and aging of the population and improvements in survival as well as trends in treatment patterns and costs of care following cancer diagnosis. In this paper, we describe measures of the economic burden of cancer and present current estimates and projections of the national burden of cancer in the US. We discuss ongoing efforts to characterize the economic burden of cancer in the US and identify key areas for future work, including developing and enhancing research resources, improving estimates and projections of economic burden, evaluating targeted therapies, and assessing the financial burden for patients and their families. This work will inform efforts by health care policy makers, healthcare systems, and employers to improve the cancer survivorship experience in the US.</p></abstract><kwd-group><kwd>cost of illness</kwd><kwd>health care expenditures</kwd><kwd>neoplasms</kwd><kwd>projections</kwd><kwd>SEER-Medicare</kwd></kwd-group><funding-group><award-group><funding-source country="United States">National Cancer Institute : NCI</funding-source><award-id>Z99 CA999999 || CA</award-id></award-group></funding-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 002A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3191884
|texte= Economic Burden of Cancer in the US: Estimates, Projections, and Future Research
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:21980008" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |